With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
It is the first autotaxin inhibitor to be investigated in cancer patients
Acquisition of exclusive commercialization rights for European markets
Collaborative Research in AYUSH is extremely important as it bridges the gap between traditional knowledge and modern scientific research
Launch of Indian public health standards for Ayush healthcare facilities
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
The product will be launched in March 2024
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Subscribe To Our Newsletter & Stay Updated
